Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AstraZeneca
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Written informed consent obtained from the patient prior to performing any protocol-related procedures
Age ≥18 years at time of study entry
Patients must have histologically or cytologically documented diagnosis of NSCLC with a locally advanced, or locally recurrent, unresectable (stage III) disease (according to American Joint Committee on Cancer \[AJCC\] lung cancer edition 8)
Patients must have completed a platinum-based chemotherapy with radiation therapy (concurrent or sequential) without evidence of disease progression
Patients must have been treated with at least one dose of durvalumab
You may not be if
Any subject who meets any of the following criteria will not qualify for entry into the study:
Absence or missing of written informed consent form
Patients treated with durvalumab in clinical studies
Absence of essential data to obtain all necessary information
Confirmation that the subject was already included in this study before
Clareo Health | A Multi-center, Non-interventional, Prospective Study of Durvalumab in Unresectable Locally Advanced NSCLC in Routine Clinical Practice in Russia
